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ON BEING A PHYSICIAN IN THE ELECTRONIC AGE: PEERING 
INTO THE MISTS AT POINT-&-CLICK MEDICINE 
ARNOLD J. ROSOFF* 
I.  INTRODUCTION 
Here, in the wee morning hours of the third millennium, we face the dawn 
of a new world of health care delivery.  It is a world electric in its dynamism 
and capacity for change.  It is also a world that is heavily electronic, that is, 
grounded upon the widespread use of computers, electronic information and 
communication technology.  Saint Louis University’s 13th Annual Health Law 
Symposium, held in April of 2001, addressed a range of issues that this new 
environment will raise, including the ethics of e-medicine, the legal framework 
for borderless medicine and the balancing of public and private interests in 
health information. 
Drawing upon my presentation at that Symposium, this Article focuses on 
two related developments—the use of Clinical Decision Support Systems and 
the growing practice of “e-prescribing”—that will affect in a fundamental way 
how physicians perform their traditional functions of diagnosing and treating 
patients.  The electronic era will bring profound changes in the art and science 
of being a physician as well as changes in the relationships physicians have 
with their patients and other parties in the health care system.  In fact, massive 
changes have already taken place, and continue to take place in health care, 
quite apart from the e-aspects addressed here.  Managed care and related 
pressures forcing cost consciousness, integrated delivery systems, the 
corporatization of health care providers and the evolution of new team and 
organizational approaches to health care delivery have already moved us well 
away from the traditional one-to-one relationship between doctor and patient.  
These underlying factors interact with the emergence of the electronic age in 
manifold and subtle ways, making it impossible to look at one without the 
other.  To give just one example, computerization of patient treatment records 
may offer substantial savings of time and effort, a change most physicians 
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would view positively.  But when this same change also enables closer and 
more constant scrutiny of physicians’ practice patterns by managed care 
entities, physicians may react quite differently—not because they object to the 
electronic innovation, but rather because they fear what may happen to them as 
a result of it.  Thus, the pace and tenor of physicians’ adoption of new 
technology may be determined by their vision of what kind of world that 
adoption will bring.  This “guilt by association” factor may make it difficult to 
assess physicians’ receptivity to the electronic changes and, thus to project the 
future of the electronic innovations. 
As noted above, this Article addresses two important innovations that will 
redefine the terrain of physician practice as we move into the e-world of the 
future: Clinical Decision Support Systems and e-prescribing.1  As to each of 
these elements, this Article will attempt to project future developments as they 
will affect clinicians practicing in the real world.  The timeframe for the 
evolution of these elements is not specified, but is assumed to be within the 
next decade.  Some of the changes will come much faster, some will be 
realized only in a limited way, some will never come and some are here 
already, at least in part.  The scenarios reflect my vision of how things will 
evolve—based in part on what I know already to be here, in part on what I 
have heard and read others saying about the future shape of things, and based 
in part, frankly, on my imagination and speculation about how things might 
come to be.  I will, of course, use my best efforts to keep these three elements 
separate—or, at the least, to identify for the reader which is which.  The 
principal problem with this last proposition, however, is the speed with which 
things are changing.  Some of what I think is fanciful projection as I am 
writing this may well mirror things that are already extant, or become so by the 
time this Article is published. 
In looking at the elements identified above, the Article will flag key 
technical, structural, practical and legal issues envisioned in connection with 
each and will point to sources that illuminate these areas.  It is not the 
objective, however, to answer—at least not in any definitive way—the 
 
 1. Two other elements of the e-revolution—e-mail communications between doctor and 
patients and the use of websites by healthcare providers as a part of their business and clinical 
practice—were touched on in my presentation at the Health Law Symposium.  Fascinating topics 
both, they are not covered here due to space limitations. 
  A number of sources provide background on healthcare websites.  See, e.g., Howard J. 
Anderson, Got a Website Yet?, INTERNET HEALTH CARE MAG., Apr. 2001, at 4; Gary Baldwin, 
Physicians Bring Color and Flair to their Web Sites, INTERNET HEALTH CARE MAG., Apr. 2001, 
at 28; Dawn Brewer, More Rules, More Risks for High-Tech Health Care Sites, THE NAT’L L.J., 
Jan. 29, 2001, at B19; Jonathan Bush et al., Navigating the Options: Using the Internet to 
Improve Doctor-Patient Relationships, HEALTH MGMT. TECH., Nov. 2000, at 22; MargaretAnn 
Cross, What’s Next? Experts Look Ahead to 2001, INTERNET HEALTH CARE MAG., Dec. 2000, at 
36; E-Lab Opportunities: What are the Real Costs and Benefits of Web-Enabled Outreach?, 
MED. LABORATORY MGMT. REP., Jan. 2001, at 1. 
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questions raised.  The Saint Louis University School of Law’s Health Law 
Symposium that spawned this issue was oriented toward crystal-balling the 
health care field and initiating a dialogue about future developments, 
consequences and implications.  We stand much closer to the beginning of that 
inquiry than the end. 
II.  CLINICAL DECISION SUPPORT SYSTEMS 
A. How CDSSs Work – an Overview 
Computer-based Clinical Decision Support Systems (CDSSs) have the 
potential to revolutionize the way medicine is practiced, affecting both the 
reality of what the physician is doing and the patient’s perception of it and, 
thus, profoundly changing an intimate relationship of very long standing.  
Simply put, a CDSS is an “expert system” that merges a powerful data base of 
health care information, including information specific to a given patient, with 
a complex set of diagnostic and treatment algorithms—commonly known as 
Clinical Practice Guidelines, or CPGs.2  Using a series of point-and-click steps, 
the CDSS walks the physician through the diagnostic process, suggesting 
questions, bringing together data inputs from various sources and ultimately 
helping to yield a diagnosis of the patient’s condition.  In many cases, it is not 
possible to render a definitive diagnosis, and a range of possibilities is given, 
often with a probability statistic associated with each.  (Example: “It is 83% 
likely that the patient has condition X but there’s a 47% probability that it is 
actually condition Y.  Given such a differential diagnosis, it is appropriate to 
treat for X but continue to gather information and watch for signs that would 
reveal whether the correct diagnosis is Y.”) 
Once a tentative, working diagnosis is reached, the system walks the 
physician through another set of algorithmic steps to determine the appropriate 
treatment, or range of possibly appropriate treatments, for each of the 
conditions identified above.  Treatment A might be the appropriate treatment 
generally for patients with Condition X; but in the case of this particular 
patient, who is suffering from another condition for which he is being treated 
concurrently, Treatment A is not indicated.  Thus, Treatment B is ordered on 
the assumption that Condition X is the problem, but with the case flagged to 
watch for signs of Condition Y and change the therapeutic approach if those 
signs manifest and the tentative diagnosis of X must be modified. 
 
 2. A representative definition says that CDSSs are systems that can “synthesize and 
integrate patient-specific information, perform complex evaluations, and present the results to 
clinicians in a timely fashion.”  Dereck L. Hunt et al., Effects of Computer-Based Clinical 
Decision Support Systems on Physician Performance and Patient Outcomes, 280 JAMA 1339, 
1339 (1998). 
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B. What Lies Beneath the CDSS?  Clinical Practice Guidelines 
CDSSs are propelled by CPGs, which, in turn, are increasingly based upon 
Evidence-Based Medicine (EBM).  Much has been written about the evolution 
of EBM and how it differs from the traditional approach to the advancement of 
medical knowledge, the latter a process far more subjective and anecdotal.3  
EBM relies heavily on outcomes research, a methodology involving the 
analysis, usually by computer, of large amounts of encounter and treatment 
data to determine what works and what does not in terms of yielding the 
desired clinical outcomes: preservation of life, reduction of symptoms, 
restoration of normal function, et cetera.4  Into this equation, the cost of 
various treatment inputs can be added, yielding an index not just of a 
treatment’s effectiveness, but also of its cost-effectiveness.  Armed with this 
analysis and the empirical data to defend it, the powers that be—whether they 
are government agencies, health plans, insurers or individual healthcare 
consumers—can decide what care should or should not be provided, what 
services should be paid for and so forth. 
The cost-effectiveness analysis briefly described above is then turned into 
CPGs.  Here again, there has been a great volume of analysis and commentary 
on developments in this area.5  Until relatively recently, CPGs were generally 
cast in the form of paper documents, often three-hole-punched for insertion 
into loose-leaf binders, with periodic updates sent to be inserted into the 
binders.  Once in the hands of affiliated physicians, these CPGs are supposed 
to guide, but not control, their treatment decisions.  While CPGs can be used, 
and historically were used, to improve and ensure the quality of care, in recent 
years, they have come to be used more often as a device for cost-containment.6  
Their parameters have been tuned to cost-effectiveness analysis (CEA) and 
they have become the tools of choice of Managed Care Organizations (MCOs) 
for assuring cost-consciousness of affiliated providers.7 
 
 3. See, eg., Cynthia D. Mulrow & Kathleen N. Lohr, Proof and Policy from Medical 
Research Evidence, 26 J. HEALTH POL., POL’Y & L. 249, 250-53 (2001). 
 4. See, e.g., Arnold J. Rosoff, Evidence-Based Medicine and the Law: The Courts Confront 
Clinical Practice Guidelines, 26 J. HEALTH POL., POL’Y & L. 327, 328 (2001). 
 5. See generally, e.g., Peter D. Jacobson & Matthew L. Kanna, Cost-Effectiveness Analysis 
in the Courts: Recent Trends and Future Prospects.  Evidence: Its Meanings in Health Care and 
in Law, 26 J. HEALTH POL., POL’Y & L. 291 (2001); Prosser, L. A. et al., Barriers to Using Cost-
Effectiveness Analysis in Managed Care Decision Making, 6 AM. J. MANAGED CARE 173-79 
(2000); Sara Singer et al., Decreasing Variation in Medical Necessity Decision Making: Final 
Report to the California HealthCare Foundation, Center for Health Policy, Stanford University, 
(Aug. 1999), available at http:/admin.chcf.org/documents/chef/medicalnec.pdf (last visited Jan. 
22, 2002). 
 6. Troyen A. Brennan, Practice Guidelines and Malpractice Litigation: Collision or 
Cohesion?,  16 J. HEALTH POL., POL’Y & L. 67, 67 (1991). 
 7. Peter D. Jacobson & Matthew L. Kanna, Cost-Effectiveness Analysis in the Courts: 
Recent Trends and Future Prospects, 26 J. HEALTH POL., POL’Y & L. 291, 294 (2001). 
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C. Will Physicians Accept CDSSs? 
Will physicians accept Clinical Decision Support Systems as the new 
infrastructure of their clinical practice?  This critical and difficult question 
basically has two parts.  The first is whether physicians will accept CPGs.  The 
second is whether they will accept them in the form of CDSSs. 
1. Physician Acceptance of CPGs 
United States physicians, in general, have not been keen to embrace CPGs 
or guide their practice decisions by them.8  There are a number of reasons for 
this.  First, many clinicians—hands-on practitioners as opposed to academic 
physicians or medical researchers—do not appear to accept, at least not fully, 
the EBM science underlying the CPGs.  They act as if they believe that 
patients are too different from each other to be lumped together for research 
purposes; therefore, these studies do not truly reveal what works and what does 
not.  Physicians have long put CPGs down with the pejorative label “cookbook 
medicine.”9  They believe, even if they may be reluctant to say so, that their 
personal observations are just as valid as—or, perhaps more valid than—the 
results of these “large n’ studies.”  Neither of these positions would be 
comfortable for them to defend, since as people of science, they routinely deal 
with statistical proof of things generated by various forms of research studies, 
including randomized clinical trials.  However, when this aspect of their 
scientific world potentially conflicts with their traditional areas of practice 
prerogative, they often find ways of challenging the science. 
For example, they may accept the concept of Evidence-Based Medicine in 
a general way but also believe that their patients, for one reason or another, 
differ sufficiently from the study group that the results of the study group are 
not applicable to, and thus should not control, their “unique” practice 
situation.10  They may also distrust CPGs because of their auspice and the 
perceived motivations of those who generate them.  There is a widespread 
 
 8. Sandra J. Tannenbaum, Knowing and Acting in Medical Practice: The Epistemological 
Politics of Outcomes Research, 19 J. HEALTH POL., POL’Y & L. 27, 37-39 (1994). 
 9. What’s in a name?  Apparently quite a bit.  WebEBM, Inc., a Nashville-based company 
that sells a service enabling physicians to go online to access guidelines aimed at standardizing, 
and thus improving, clinical care, promotes its online applications as “Evidence-Based 
Medicine,” believing this term has a much more positive connotation and acceptance among 
physicians than “clinical practice guideline.”  Gary Baldwin, Bringing Docs Online Takes Tact, 
INTERNET HEALTH CARE MAG., Jan./Feb. 2001, at 32, 34 [hereinafter Baldwin, Bringing Docs 
Online].  WebEBM represents a collaboration involving the medical schools at Duke, Emory, 
Oregon Health Sciences University and Washington University. 
 10. It is ironic how consistently people are ready to generalize from their own particular 
situation; that is, to believe that what they have personally experienced reflects the world at large 
while, at the same time, harboring a deep-seated unwillingness to believe that what is known to 
be true in general actually applies to their particular situation. 
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concern, not unfounded, that the guidelines are being used primarily by 
managed care “bean-counters” to ration care and limit the doctor’s autonomy 
and judgment in providing for his or her patients what the patients actually 
need.  Finally, physicians may be wary of following CPGs for fear that the 
patient care actions they take to comply with CPGs may expose them to 
liability because of the way CPGs relate, or fail to relate, to traditional legal 
principles measuring the adequacy of physician performance by reference to 
standard professional practice.11 
Important as these philosophical and legal factors are, it may be that the 
compelling factor that has tended to discourage physicians, as a practical 
matter, from following CPGs—and perhaps indirectly has motivated them to 
find justifications for not believing in them—is the sheer difficulty of keeping 
up to date with the CPGs.  Because they have to be revised relatively 
frequently as medical knowledge advances, CPGs represent a substantial 
burden to physicians in terms of just staying current with the release of new 
guidelines and interpretations.12  This is especially the case where a physician 
participates in a number of different MCOs, a common situation nowadays.  In 
such situations, she or he has to keep track of several different sets of 
guidelines—knowing not only what the guidelines say on their face but also 
how they are implemented in practice—and also has to remember when 
treating a patient which health plan, and thus which set of guidelines, governs. 
2. CDSSs as a New Form of CPGs 
For the reasons discussed above, and perhaps others, many physicians have 
been reluctant to embrace guidelines.  However, their response to CDSSs 
might well be different.  In the emerging e-world of health care, CPGs will not 
often come to doctors in the form of hard-copy documents, meaning, paper 
supplements to be stuffed into already-bulging loose-leaf binders.  Rather, they 
will be integrated into elaborate, computer-based systems that will be a 
standard fixture in every practitioner’s office.  Not only will the physical form 
of these CPGs be different, but their entire orientation will be reversed and 
they will be promoted in a very different way.  Instead of constraints or 
additional obligations that the physician has to satisfy, CPGs, offered in the 
form of point-and-click CDSSs, will be promoted as tools to make the 
physician’s job easier.  In such a guise, they may be received more 
enthusiastically and may go much further toward changing physician practice 
patterns.  This is true even though CDSSs may effectively enable much greater 
 
 11. See Rosoff, supra note 4, at 335-46. 
 12. One can argue that the burden is not that different from the burden resting on all 
professionals to stay current with developments in their fields.  However, that general burden is 
placed on physicians by their own pride and conscience and so, perhaps, is not seen as an outside 
imposition but rather as a matter of personal choice. 
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external control by MCOs of physician behaviors, something doctors would 
normally resent and resist.  As Dr. Homer Chin, a practitioner in the Kaiser 
Health Plan network, said in presenting a proprietary CDSS at a major national 
healthcare information technology conference, “If you make it easy for doctors 
to do the right thing, they will do the right thing.”13 
Computerized CDSS tools have the potential, if well designed and properly 
used, to ease rather than increase the burdens of the physician’s practice—at 
least once the initial period of learning how to use the system is past.  Instead 
of guidelines being one more aspect of information overload that physicians 
have to use their valuable time and attention to manage, the CDSS will help 
them manage other aspects of their workload and, at the same time, help assure 
that they will not overlook something important, such as a late-breaking piece 
of medical information that might bear on the patient’s treatment.  Certainly as 
both the volume of information and the pace of change increase, the burden on 
physicians’ memories will become greater.  Computers offer the ability to 
manage an enormous volume of rapidly changing information and bring key 
bits forward at the right time and place and in a useful way.  This may be just 
the right time and place for these e-devices to come to the aid of overworked 
and overstressed medical practitioners. 
The medical world of the future will undoubtedly be one with many more 
constraints and limits.  Our recognition that health care resources are finite 
makes this a virtual certainty.  As doctors today contemplate a world with 
more monitoring, supervision, rules and limitations, the future, not 
surprisingly, looks bleak.  The reality is, however, that the electronic era not 
only enables close scrutiny, it can also facilitate integration of physicians into a 
health care network in ways that lessens, rather than adds to, their burdens.  
We are certainly not at that point yet.  Our understanding of the problems has 
to evolve further before our search for solutions can proceed effectively.  The 
simple message is that the future is not all dark; there are points of light—
perhaps not a thousand of them, but enough to offer hope. 
D. How Will CDSSs Change Doctor-Patient Relationships? 
It is interesting to ponder how CDSSs will affect the way doctors and 
patients relate to each other.  One might think, simplistically, that any device 
that enables doctors to provide better care would improve doctor-patient 
relationships, but perhaps there is another side to the picture—the loss of the 
physician’s mystique as healer and the decline of the “art of medicine.” 
The logical, multivariate reasoning process described above under the 
discussion of how CDSSs work has been used by physicians since time out of 
 
 13. Homer Chin, Remarks at the HIMSS annual meeting in Atlanta, Ga. (Feb. 23, 1999) 
(presenting the Epic Systems Corp. CDSS).  For information about the Epic Systems Corp., 
located in Madison, Wis., contact Susan Effinger at 608-271-9000. 
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mind.  Before the advent of computers, it carried—and still carries today—
such honorific labels as “clinical judgment” and “professional expertise.”  The 
ability to collect information, organize it, think through a medical problem and 
come up with principal and alternative diagnoses and therapies goes to the core 
of what physicians do, and have done since they first existed.  The key to the 
process has always been the store of knowledge the physician carries, locked in 
his or her gray matter; and much of the respect and authority that physicians 
have enjoyed through the ages has come from patients’ awe at the perceived 
quantity and quality of that knowledge.  Now, ironically, as physicians are able 
to augment the knowledge in their heads with a continuously updated and 
expanding store of electronically retrievable information,14 and thus increase 
the accuracy and effectiveness of their treatments, the patient’s respect for the 
physician might actually diminish.  The key question is how much of that 
respect comes from that indefinable something known as mystique. 
Previously the physician’s thought process was largely invisible to the 
patient.  Now, watching a physician point and click his way through a CDSS 
program, the patient may find himself thinking that he, the patient, has used 
similar programs to find the lowest airline fares or rental car rates.  If he 
perceives that the doctor is just doing the same thing he himself has done, 
albeit with a more sophisticated and esoteric guidance system, the mystique of 
the knowledgeable healer may be significantly eroded.  Assuming this is true, 
how the physician handles his or her use of the CDSS may make a big 
difference.  For example, consider how much different a dynamic is created if 
the doctor sits side-by-side with the patient and they watch the screen together 
while the doctor manipulates the mouse than if the doctor sits behind a desk 
and looks past the screen at the patient, with the screen hidden from the 
patient’s view.  If the patient is aware that the doctor is essentially being 
guided through a detailed process, practicing “cookbook medicine” using an 
electronic cookbook, is the therapeutic environment undermined?  Will the 
patient transfer his respect to the computer programmer, or to the company that 
supplies the CDSS, or will that respect simply dwindle?  A magician’s most 
clever trick loses its wonder when you can see how it is done.  How important 
is the mystique of the learned clinician to the therapeutic process? 
Perhaps the physician’s mystique is not that central to the patient’s 
perception of his or her professional competence, after all.  Perhaps in the 
electronic age it will be replaced by a better-informed, ultimately healthier, 
appreciation of the physician’s expertise in the use of computers, databases and 
 
 14. Dr. Andrew Spooner, Director of Pediatrics at the University of Tennessee at Memphis, 
cites the ability to stay on top of clinical research as a prime reason for using the Internet.  He 
uses, among other services such as Medline and MDConsult, an online library of 40 clinical 
journals accessible for a $200/year subscription.  See Baldwin, Bringing Docs Online, supra note 
9, at 36. 
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the Internet.  Patients may be drawn to physicians who are adept at using these 
new e-tools, seeing that as the relevant professional expertise in the new 
millennium—or, at least, a major part of it.  As discussed below, patients may 
also seek out physicians who offer them other convenience benefits of the e-
age, such as e-mail communications, online appointment scheduling, e-
prescribing, et cetera.15 
If patients are intrigued and attracted by the high-tech appeal of CDSSs, 
how will they evaluate the quality of the care the systems are capable of 
providing?  An old theme may emerge—the contest between style and 
substance.  Imagine two CDSSs developed and put in place in physicians’ 
offices by two competing MCOs.  One MCO invests a substantially greater 
proportion of its funds available for this use in state-of-the-art computer 
technology, with attractive (perhaps even animated) graphics, a more user-
friendly interface, and more visible “bells and whistles”—a fancy “front-end,” 
to use e-systems lingo.  The other MCO devotes the greater proportion of its 
CDSS budget to support more exhaustive, more technically sophisticated, 
analysis of the underlying EBM research—in other words, a more solid, 
substantive “back-end.”  The second system is “clunkier,” superficially less 
appealing, but let’s assume it has notably “better medicine” as its foundation.  
Which would the patient find more impressive?  Which would physicians be 
more drawn to using?  Might this not be the new-age equivalent of the old 
dilemma: should one choose a doctor who is technically more skilled or a 
doctor who has a better “bedside manner” (or even a more handsomely 
decorated office or more up-to-date magazines in his waiting room)?  When 
the question is phrased this starkly, the answer seems clear; one would, 
presumably, always choose competence over “cosmetics,” meaning, superficial 
factors, such as appearance or amenities.  In practice, however, the choice may 
not be so clear-cut, in large part because competence is much harder for a 
prospective patient to assess than other factors that are admittedly less 
important but more readily discernible.  How would a patient evaluate the 
quality of a decision support system?  Might there come a time when 
developers of CDSSs would engage in image-building advertising aimed at 
health care consumers rather than practitioners?  Imagine a TV commercial 
saying, “What kind of decision support system does your doctor use?  Ask her 
the next time you go in for a visit.  If she doesn’t answer, ‘I use the new HAL 
9000 series,’ maybe it’s time to look for a new doctor!”  Will direct-to-
consumer advertising in the e-age ever come to this?  Think about it! 
E. Practical and Legal Considerations 
Fostering an increasing reliance by physicians on electronic decision 
support devices raises some interesting, but also troubling, questions.  First and 
 
 15. Id. at 37. 
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foremost, of course, is where the responsibility lies when something goes 
wrong.  Electronic interactions generally leave an excellent “audit trail,” so 
determining the factual issues underpinning an iatrogenic event may be easier 
than it is currently in the more traditional world of health care delivery.  Even 
with the facts nailed down, the legal issues may be complex.  Who is 
responsible for errors in the CDSS program—or for errors made by the 
physician in following its guidance, or in not following its guidance 
accurately?  Would the developers of the CDSS, or its underlying CPG, be 
liable if its use caused harm to someone? 
To the extent that current law might offer an answer to this last question, 
one would expect that answer to be in the negative.  The authors of a flawed 
research study that is relied on by a physician to the patient’s detriment are not 
liable to the patient,16 nor is the journal that published the study.17  In addition 
to public policy arguments against stymieing medical progress by chilling the 
widespread sharing of new ideas, these results rest on the fundamental notion 
that it is the physician himself on whom responsibility should rest.  The 
physician chooses what sources to turn to and what information to use in his or 
her decision-making process.  It is the physician’s educated discretion that 
finds, filters and focuses these inputs for the benefit of the patient; thus, it is 
appropriately the physician’s exercise of that discretion that is the focus of the 
legal inquiry.  The physician’s thought process serves as “insulation,” so to 
speak, for those who stand behind him or her and provide information inputs.  
There is a ready analogy to this in the “learned intermediary” doctrine in 
pharmacy law18 and an even more pointed reference in the Food and Drug 
Administration’s concept of competent human intervention (CHI), as detailed 
in the FDA’s medical software policy pronouncements.  It is this CHI concept 
 
 16. Nicolas P. Terry, Cyber-Malpractice: Legal Exposure for Cybermedicine, 25 AM. J.L. & 
MED. 327, 353 (1999). 
 17. Id. (citing Jones v. J.B. Lippincott Co., 694 F. Supp. 1216, 1216-17 (D. Md. 1988)). 
 18. For an overview of the “learned intermediary” doctrine, see Hernandez v. Ciba-Geigy 
Corp., USA, 200 F.R.D. 285, 294 (S.D. Tex. 2001). 
  For cases involving a drug manufacturer’s duty to warn, . . . courts apply the 
“learned intermediary” doctrine.  Under that doctrine, a physician stands as an 
intermediary between a product manufacturer and the patient.  The manufacturer satisfies 
its duty by warning the physician of the dangers of the drug.  The product manufacturer 
relies on the physician to pass on its warnings.  The physician, relying on his medical 
training, experience, and knowledge of the individual patient, then chooses the type and 
quantity of drug to be prescribed.  “Once the physician is warned, the choice of which 
drugs to use and the duty to explain the risks become that of the physician.” 
Id. (citations omitted). 
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that will likely serve as the base point for the current analysis, but CHI is a 
slippery notion that has generated much of controversy.19 
1. FDA Regulation of Medical Software and the CHI Concept 
For the past quarter-century, the FDA has had the legislative authority, 
under the Medical Device Amendments of 1976,20 to regulate medical devices, 
defined as 
an instrument, apparatus, implement, machine, contrivance, implant, in vitro 
reagent, or other similar or related article, including any component, part, or 
accessory, which is . . . intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment or prevention of disease, in 
man or other animals.21 
 The authority clearly extends to software that is integral to, or closely 
connected with, hardware that one would normally think of as a medical 
device—such as equipment involved in the physical delivery of patient care.  
Examples would include the software that operates a CAT scanner or software 
used to monitor a patient’s vital signs and regulate a respirator based upon that 
monitoring.  Less obvious is the FDA’s authority to regulate “stand alone” 
medical software, such as that used to operate epidemiological information 
databases, patient electronic medical records and CDSSs.  Although in a 1989 
draft policy Guidance memorandum,22 the FDA declared unclassified medical 
software products to be medical devices and, thus, potentially subject to FDA 
regulation—defining the scope of its authority expansively—it had earlier 
articulated a policy decision to “apply the least possible regulatory action 
required by law to fulfill our public health responsibility.”23  Thus, the 1989 
Guidance exempted computer products intended only for use: 
 
 in traditional “library” functions, such as storage, retrieval and 
dissemination of medical information 
 
 
 19. See, e.g., Dee Simons, Medical Device Software Regulation: An Industry Perspective, 52 
FOOD DRUG L.J. 189, 190 (1997); E. Stewart Crumpler & Hargey Rudolph, Ph.D., FDA Software 
Policy and Regulation of Medical Device Software, 52 FOOD DRUG L.J. 511, 513-14 (1997). 
 20. 21 U.S.C. § 360(c) (1994). 
 21. Id. § 321(h). 
 22. U.S. FOOD & DRUG ADMIN, CTR. FOR DEVICES & RADIOLOGICAL HEALTH, FDA Policy 
for the Regulation of Computer Products, (Draft) (Nov. 13, 1989), available at 
http://www.fda.gov/cdrh/ode/351.pdf (last visited Jan. 16, 2002) [hereinafter FDA 1989 Draft 
Policy]. 
 23. Former FDA Commissioner Frank E. Young made this statement in 1986.  U.S. FOOD & 
DRUG ADMIN., CTR. FOR DEVICES & RADIOLOGICAL HEALTH, FDA Software Policy Workshop 
(Sept. 3-4, 1996), FDA Regulation of Medical Device Software: Background Information, 
available at http://www.fda.gov/cdrh/ost/points.html (last visited Jan. 16, 2002). 
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 in general accounting or communication functions; or 
 
 solely for educational purposes, rather than for diagnosis or treatment of 
patients24 
 
Moreover, the Guidance stated that the FDA did not contemplate regulating 
computer products “that are intended to involve competent human intervention 
before any impact on human health occurs, (for instance, where clinical 
judgment and experience can be used to check and interpret a system’s 
output.)”25  The idea was, of course, that the software would be exempt from 
regulation if, in the ordinary course of using it, a knowledgeable professional 
would be in a position to interpret and, if necessary, override its 
recommendation. 
Making the exemption turn on competent human intervention seems a 
reasonable approach in concept, but it has proved troublesome in practical 
application.  Manufacturers reportedly have misconstrued the exemption in 
order to apply it more broadly than the FDA intended.  Moreover, and more to 
the point of our present discussion, the increased use and sophistication of 
medical software, and the presumably greater reliance of physicians on 
systems utilizing such software makes it ever more difficult to apply the CHI 
concept.  Thus, the FDA has more recently, in 1996, moved beyond the CHI 
concept to a more comprehensive risk assessment concept that classifies 
medical software on the basis of the following five factors: 
 
 the seriousness of the disease or condition being diagnosed or treated, 
 
 the amount of time available before the practitioner uses the information 
provided by the software, 
 
 whether the data output departs from customary use or data presentation, 
 
 whether the information is individualized for each patient, and the 
relative risk to the patients if the software fails, and 
 
 the extent to which the practitioner would be exercising independent 
judgment in assessing the conclusion reached by the software.26 
 
 24. See FDA 1989 Draft Policy, supra note 22, at 1. 
 25. Id. at 3 (emphasis added). 
 26. U.S. FOOD & DRUG ADMIN., CTR. FOR DEVICES & RADIOLOGICAL HEALTH, FDA 
Software Policy Workshop (Sept. 3-4, 1996), Classification and Risk-Based Criteria, available at 
http://www.fda.gov/cdrh/ost/classif.html [hereinafter FDA, Classification and Risk-Based 
Criteria].  See also Dee Simons, Symposium—Drug Development: Who Knows Where the Time 
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Based on these factors, software applications are classified as high-, 
moderate-, or low-risk and this classification affects the strictness of the FDA’s 
scrutiny and the fullness of the regulatory requirements.27  This new five-
pronged test is not necessarily easier or more certain in its application than the 
old CHI approach, especially since the CHI factor is folded into it and remains 
an important component.  However, under the new approach, the slippery CHI 
determination is now just one of a number of factors, not in itself determinative 
of exemption from FDA regulation.  Also, the decision on regulation is no 
longer an all-or-nothing decision, since different levels of regulation are 
possible.  Whether, given the subtlety of the other factors in the new test, it is 
more workable than the old is not an easy judgment call.  For one thing, in the 
five years since the “new” test was introduced, there have been substantial 
changes in the sophistication of medical software, in the extent of its 
dissemination and adoption, and in the degree to which practitioners routinely 
rely upon it in making diagnostic and treatment decisions.  Thus, there are 
important new developments and environmental factors bearing on any 
assessment of the FDA’s regulatory strategy. 
That strategy remains essentially the same as before—to “use the least 
amount of regulatory control necessary to control risks” and, further, to 
“regulate medical software devices innovatively to minimize impact on 
product development.”28  The industry, not surprisingly, has pushed the FDA 
to adopt a low-intervention policy, fearing that the costs, cumbersomeness and 
constraints of aggressive regulation could seriously impede the development 
and adoption of new software innovations and applications.29  The challenge 
for the regulators is, of course, a common one: walking the fine line between 
responsibly protecting the public against inadequately tested and unproven 
innovations on the one side and, on the other, not overly encumbering and 
chilling a promising new field of health care technology. 
Although the topic is intrinsically interesting and worth pursuing, a fuller 
exposition of FDA regulation of medical software is beyond the intended scope 
of this Article.  In closing on this general area, however, two other points are 
 
Goes?  Medical Device Software Regulation: An Industry Perspective, 52 FOOD & DRUG L.J. 
189, 191 (1997). 
 27. FDA, Classification and Risk-Based Criteria, supra note 26. 
 28. E. Stewart Crumpler & Harvey Rudolph, FDA Software Policy and Regulation of 
Medical Device Software, 52 FOOD & DRUG L.J. 511, 514 (1997). 
 29. See CTR. FOR HEALTHCARE INFO. MGT., RECOMMENDATION TO THE FOOD AND DRUG 
ADMINISTRATION FOR “STAND-ALONE” SOFTWARE MEDICAL DEVICE DECISION ALGORITHM 
17-18 (Mar. 18, 1997), available at http://ww.chim.org/pdfs/1997StandAloneAlgorithm (last 
visited Nov. 8, 2001); Randolph A. Miller & Reed M. Gardner, Recommendations for 
Responsible Monitoring of Clinical Software Systems, 4 J. AM. MED. INFORMATICS ASS’N 442, 
443 (1997). 
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worth noting.  One is the question of what constitutes “commercial 
distribution” of software, a significant issue because only commercially 
distributed software is subject to FDA regulatory control as a medical device.30  
Software that is shared “in-house” among users and developers “solely for 
research purposes” is exempt.31  Since CDSSs are still, one could well argue, 
in a developmental stage, the form of the relationship between a CDSS vendor 
and a customer, such as an MCO, might determine whether it is subject to 
FDA regulation.32  The other point to note is the FDA’s proposal to use 
software quality audits in lieu of the Agency’s traditional 510(k) process as a 
safeguard of quality.33  Again, it is not this Article’s intent to delve into the 
intricacies of FDA regulation but, rather, to raise the policy question of how 
much and what kind of regulation best serves society’s interest in responsible 
development of medical software applications. 
2. Liability of Software Developers 
Quite apart from FDA regulation, there is the possibility of common law 
liability on the part of the developers and sellers of CDSSs (hereinafter 
“vendors”).  As between a vendor and a provider group that uses its system, 
that liability would turn significantly, but not solely, on the nature and details 
of the vendor’s undertaking.  It is to be expected that vendors will attempt to 
cover their liability exposure either by contractual disclaimers or by insurance.  
The latter approach, coupled with a contractual undertaking to indemnify and 
hold harmless the health care professionals using the CDSS, would seem to be 
the better market strategy, counteracting possible concerns of providers that by 
using a new, largely unproven, software tool they would be exposing 
themselves to significant liability potential.  However, the feasibility of this 
approach would necessarily turn on the price of the liability insurance, which 
 
 30. U.S. FOOD & DRUG ADMIN., CTR. FOR DEVICES & RADIOLOGICAL HEALTH, FDA 
Software Policy Workshop (Sept. 3-4, 1996), Commercial Distribution, available at 
http://www.fda.gov/cdrh/ost/distrib.html (last visited Jan. 16, 2002). 
 31. Bruce Merlin Fried & Jason Mark Zuckerman, FDA Regulation of Medical Software, 33 
J. HEALTH L. 129, 139 n.30 (2000). 
 32. Of course, using the terms “vendor” and “customer” begs the question.  Should these 
parties want to escape FDA control, they would certainly not structure their relationship so as to 
make these labels seem appropriate. 
 33. The FDA’s 1996 policy workshop paper defines the Software Quality Audit as: 
a critical review of the software quality assurance system, performed by a qualified and 
independent third-party quality auditor, to provide documentary evidence that a particular 
medical software device was developed in accordance with appropriate industry standards 
or according to a recognized quality process, specification, and procedure established by 
the developer. 
U.S. FOOD & DRUG ADMIN., CTR. FOR DEVICES & RADIOLOGICAL HEALTH, FDA Software 
Policy Workshop (Sept. 3-4, 1996), An Alternative to Current Premarket Notification (Software 
Quality Audit), available at http://www.fda.gov/cdrh/ost/sqa.html (last visited Jan. 16, 2002). 
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would have to be built into the price of the product, the CDSS.  Given the 
cutting-edge nature of the product and the lack of legal precedents in this area, 
it would be difficult for the insurer’s actuaries to project the liability potential; 
thus the cost of the insurance might be steep. 
Contractual liability occurs when a vendor promises one thing in the 
contract and then does not fully deliver on that promise.  A recent 
advertisement by a company called Healthwise, Inc.34 describes the health 
information service it provides to healthcare consumers this way: 
Evidence-based medicine is changing medical practice.  Outcomes research is 
systematically revealing the risks and benefits of different treatments for the 
same condition.  Doctors are finding more reasons to follow practice 
guidelines based on this research.  When patients have access to the same 
evidence-based information as their doctors, better health decisions are made.  
Where medical science is not clear, or issues are controversial, Healthwise 
provides a balanced and unbiased view that allows the individual to make a 
well-informed judgment.35 
Healthwise claims that all of it’s decision-support information is referenced to 
the best evidence-based sources available and that the reader knows who wrote 
it, who reviewed it, on what research it was based and when it was last 
reviewed and updated.  Healthwise also claims that it seeks experts in every 
medical specialty to review and critique every piece of its medical 
information.36  Inherent in this advertising text are several promises that a user 
of the information service might later claim were not met.  For one thing, “the 
best evidence-based sources available” is a judgmental statement that could 
support an argument if certain sources were either overlooked or deliberately 
not included in the information base.37  For another, the claim that “[t]he reader 
knows . . .when it [the research] was last reviewed and updated” can be read to 
mean that information available as of the last update was adequately folded 
into the analysis.38  In either case, there could be potential for liability if 
important medical developments were not included in the information base—
for example, a recently discovered contraindication to a treatment that the user 
of the service could claim would have caused him or her to decline that 
treatment if he had known about it.  Note that the example above is not 
 
 34. Healthwise, available at http://www.healthwise.org/index2.html (last visited Jan. 16, 
2002). 
 35. Healthwise, About Us: Prescription-Strength Information Tools from Healthwise, at 
http://www.healthwise.org/ps_prescription.html (last visited Jan. 16, 2002).  The Healthwise 
service is marketed as being intended for patients, not for providers.  However, the liability bases 
would be largely the same in either case.  The difference lies in the “learned intermediary” 
concept, which is discussed just below in the text. 
 36. Id. 
 37. Id. 
 38. Id. 
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extravagant in its claims, making the point that even a conservatively worded 
advertising statement can hold potential for contractual liability. 
If the information service described above were intended for use by the 
physician, it is unlikely that the vendor would have significantly more liability 
potential than the publisher of a journal—except, possibly, where the vending 
contract was held to have made more extravagant promises and those promises 
were not countered by adequate disclaimers.  When one provides information 
to a health care professional, it can reasonably be assumed that the professional 
will subject that information to all the usual “filters” and will not rely upon that 
information to the exclusion of other appropriate sources.  This is the core 
premise of the “learned intermediary” doctrine.  Moreover, the information is 
provided in a format whereby the professional is expected to read, analyze, 
check and otherwise “digest” it before making a treatment decision.  This is the 
competent human intervention (CHI) upon which the FDA exemption 
described above was predicated.  Even where the information was intended for 
the patient himself, this concept might apply, on the theory that the plaintiff 
would not take any action based on the information except in consultation with 
the attending physician—again engaging the professional’s judgment and 
“filter.” 
3. Justifiable Reliance by the Provider 
The analysis leads back, then, to the linked questions of how much and in 
what way physicians will rely upon CDSSs and to what extent the law will 
regard such reliance as legitimate.  As long as it is reasonable to assume that 
the CDSS only provides information that is subject to CHI, the rationale that 
underlies the “learned intermediary” doctrine will apply, and the responsibility 
will continue to rest primarily on the physician.  But at some point, arguably, 
CDSSs will become so commonplace, so standard a part of the physician’s 
tool-set and practice routine, that physicians will be justified in relying wholly 
upon them.  To illustrate, imagine the following situation: 
Dr. X uses a digital thermometer to take an infant’s temperature.  The 
instrument suffers a non-obvious failure and registers “normal” although, in 
fact, the child has a fever high enough that, if known, would call for the doctor 
to begin immediate antibiotic treatment.  Upon seeing the “normal” readout on 
the instrument, Dr. X momentarily doubts it, because the child feels feverish to 
his touch, but then decides to rely upon the instrument.  The child comes to 
harm because of the resulting delay in treatment. 
The question, of course, is to what extent the physician is entitled to rely 
on the electronic “diagnosis support” device.  In the example just described, 
the digital thermometer would be classified as a medical device, subject to 
FDA regulation and that classification would bear significantly on, but 
probably not be fully determinative of, the physician’s potential liability for 
negligence in relying on the device.  In other words, just because a device is 
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FDA-regulated upon the premise that its output might be used by a physician 
without a separate confirming analysis—meaning, without competent human 
intervention—it is not necessarily the case that the physician is free of liability 
for “overly relying” on the device.  The question would be, presumably, to 
what extent a reasonable and prudent physician would have relied on the 
device’s output under the circumstances.  Obviously, the greater the potential 
risk to the patient if the device were defective, the more responsibility the 
physician would have to doubt the device’s output and seek independent 
confirmation of its readings.  Note how this analysis borrows from and follows 
the “risk-based” approach, described above, that the FDA has adopted for 
classification of medical software. 
Even with powerful diagnostic tools becoming more commonplace, 
physicians will likely continue for some time to rely principally upon their own 
powers of observation, judgment and intuition in treating their patients.  Even 
as Dr. McCoy on the original Star Trek series used his “medical tricorder” to 
diagnosis a patient’s condition, he continued to place great reliance on his own 
human intuition.39  But in Star Trek – The Next Generation, the medical officer 
was much more comfortable relying upon computer-based diagnostic devices; 
and in the generation after that (Star Trek – Voyager), the doctor was a 
computer-generated hologram.  One can scarcely expect a physician to distrust 
the medical software when he himself is a sub-program of that software!  We 
obviously have a long way to go before our physicians are literally creatures of 
the medical software we are now discussing, but it is not so fanciful to project 
a day when heavy reliance upon medical software becomes the rule. 
Now, for a more challenging contrast to the digital thermometer 
hypothetical above, imagine the following scenario: 
Dr. B uses a CDSS in deciding what drug to prescribe for a patient’s condition.  
Knowing that the patient’s electronic medical record (EMR) is supposed to 
contain information about all medications the patient is currently taking and 
that the CDSS is programmed to flag potential drug-drug interactions, she 
relies upon the CDSS’s recommendation without taking the time to ask the 
patient if he is taking any other medications.  As luck would have it, the patient 
is on a drug, prescribed a week before by Dr. A, that should not be taken 
concurrently with the one Dr. B is now prescribing.  The patient assumes Dr. B 
knows about the medication previously prescribed by Dr. A and makes no 
mention of it; and the patient suffers a serious adverse reaction from the drug 
interactions.  Upon investigation, it is found that either Dr. A failed to enter the 
prescription properly, the CDSS software “mis-posted” that information and it 
 
 39. As Dr. McCoy stated in Star Trek, “Dammit, Jim, I’m a physician.”  Star Trek is a set of 
television series and movies produced by Paramount Pictures Corporation.  Star Trek (The 
Original Series) aired from 1966 to 1969.  Star Trek: The Next Generation aired from 1987 to 
1994.  Star Trek: Voyager aired from 1995 to 2001.  For more information, see the Star Trek 
website, at http://startrek.com/library/episodes.asp (last visited Jan. 16, 2002). 
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never made its way into this patient’s record, or the information was correctly 
posted but the CDSS program failed for some reason to flag the drug 
interaction potential. 
Who would be liable – Dr. A, Dr. B, the CDSS vendor or some combination of 
these parties?  You decide!  In so doing, however, keep in mind that you will 
necessarily be making an underlying assumption as to how much Dr. B is 
entitled to rely upon her computer-based decision support system.  Moreover, 
even if you find that the precipitating error in this case was that of Dr. A, who 
failed to enter his prescription properly, you might find the CDSS company 
responsible for negligent design of its system—meaning, absence of a “fail-
safe” feature—that allowed the prescription to be filled without its being 
properly entered in the patient’s EMR.40 
To end this section by saying “in conclusion,” or anything of like effect, 
would be misleading folly.  There are no conclusions in sight as to any of the 
issues raised above, only questions and more questions.  Courts that are not 
fully sensitive to all that is going on in the development and 
dissemination/adoption of CDSSs may try to deal with questions of liability by 
adhering to traditional notions of physician responsibility, such as those 
underlying the learned intermediary doctrine.  However, this is an overly 
simple approach that disregards important realities of how practices of 
physicians will evolve in the electronic age.  Up to a point, the law can 
disregard realities, either consciously or unwittingly, and at times they have 
done that in the name of public policy.41 
4. The Impact on Medical Education 
It is interesting to ponder how the increasing availability and use of CDSSs 
will affect medical education in the United States.  For one thing, a physician 
who has ready e-access to comprehensive data need not spend much of his or 
her education internalizing that data.  In fact, if the data is changing rapidly, 
committing it to memory would be inadvisable and a waste of time.  For 
 
 40. Safeguards against this sort of thing happening will be touched on in the upcoming 
discussion of e-prescribing.  See infra Part III. 
 41. See, e.g., Schultz v. Mutch, 211 Cal. Rptr. 445, 450 (Cal. Ct. App. 1985) (upholding the 
“captain of the ship” doctrine).  Another California court of appeals struck down this doctrine as 
being no longer supported by actual practice in health care delivery.  See Truhitte v. French 
Hosp., 180 Cal. Rptr. 152 (Cal. Ct. App. 1982).  The Truhitte court said: “A theory that the 
surgeon directly controls all activities of whatever nature in the operating room certainly is not 
realistic in present day medical care.”  Id. at 160.  The Schultz court did not take issue directly 
with this view of the “real world” but countered with its belief that it is in the patient’s interest to 
focus legal responsibility on the physician whom the patient chose “presumably based on faith in 
his competence and expertise.  The patient reasonably expects the doctor to oversee her care and 
to look out after her interests while in and immediately pending surgery.”  Schultz, 211 Cal. Rptr. 
at 450. 
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another, it may take significant training and practice to prepare a physician to 
use the various e-tools of his or her trade naturally and confidently.  Thus, if 
one assumes continuation of the standard four-year medical school program, 
there will inevitably be shifts in the curriculum from traditional topics to new 
computer-oriented skills training.  It is hard to predict how substantial those 
shifts will be, for two readily apparent reasons, and perhaps others. 
First, computers are becoming so prevalent in every stage of education, 
from grade school onward, that students reaching medical school may already 
have an almost intuitive command of them.  Second, there are so many new 
developments in medicine—for example, genomics, “smart” medicines and 
nano-technology, that these will compete powerfully with e-subjects for space 
in the evolving curriculum.  But, while predictions are difficult to make, it 
seems fairly certain that medical education will move away from the goal of 
committing current information—that is, the information current during the 
student’s four years in school—to memory and in the direction of teaching 
students how to access the constantly expanding database that is modern-day 
“medicine in motion.”  As part of this transition, students will become more 
and more dependent on the electronic databases and less on their own personal 
memory banks—or, to put it differently, their personal memory banks will be 
used not so much to store medical information as to store the knowledge of 
how to manipulate their computer tools.  If this is so, how will it bear upon the 
question that kept recurring above: to what extent will the law endorse or 
condone a physician’s reliance upon the computerized information?  In the 
new e-world of medicine, the term competent human intervention may come to 
mean something quite different than it does today. 
III.   E-PRESCRIBING OF PHARMACEUTICALS 
Another aspect in which the future is already upon us is “e-prescribing.”  A 
number of pioneer systems are in place today,42 and the healthcare system in 
the United States is clearly moving toward establishing electronic links 
between physicians and pharmacists to facilitate ordering and dispensing 
prescription drugs more efficiently and safely.  The advantages of e-
prescribing are important and obvious and there are few voices, if any, raised 
in opposition to this trend.  However, there are substantial obstacles to be 
overcome before e-prescribing is a fully realized feature of the health care 
system. 
 
 42. For a list of the major companies offering hand-held electronic prescribing systems, see 
Institute for Safe Medication Practices, White Paper, A Call to Action: Eliminate Handwritten 
Prescriptions within 3 Years! (2000), available at http://www.ismp.org/MSAarticles/ 
Whitepaper1.html (last visited Jan. 8, 2002) [hereinafter ISMP White Paper]. 
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A. Point-of-Care Systems 
E-prescribing is an application of what are generically called “point of 
care” (POC) medical information systems.  Such systems allow the treating 
physician to bring all information elements bearing upon the patient’s care 
together at a single point when diagnostic and treatment decisions have to be 
made or implemented.  Imagine the myriad situations when, for example, a 
doctor is seeing a patient and needs a radiological study, or test results from the 
medical or pathology laboratory, or a specialist’s consultation report in order to 
decide upon the patient’s treatment regimen.  The relevant information may 
have been generated hours or even days before, but if the doctor cannot access 
it currently, the patient’s treatment is stalled.  The electronic era offers exciting 
possibilities for “shrinking time and space” and bringing all necessary data 
together when and where needed.  Moreover, a “smart system” does not just 
rely on the treating physician to ask the right questions and call for the right 
information.  It can prompt, suggest, and remind; and, thus, it can protect 
against human error and oversight.  Hand-held Personal Digital Assistants 
(hereinafter “PDAs”), known to many as Palm Pilots,43 have the potential to 
make the patient’s traditional medical and nursing charts—collections of 
scraps of paper held together in a manila folder or on a clipboard—obsolete. 
When these systems are used for the ordering of tests and medications, the 
process is known as e-prescribing, and it has been widely proclaimed as the 
“next thing” in healthcare delivery.  E-prescribing is a logical next step in the 
evolution of e-health for a number of reasons.  First, the electronic 
infrastructure it requires is closer to the reach of most physicians than that 
required for the more sophisticated CDSSs discussed above.  Some form of 
Electronic Medical Record (EMR) is at the base of most e-prescribing systems, 
but e-prescribing does not require a full-featured EMR system like a CDSS 
does.  It has to have patient identification data and information on what drugs 
have been dispensed for the patient; but full information on the patient’s 
condition, medical history, test results, et cetera, is not needed to accomplish 
the e-prescribing piece.  Second, e-prescribing does not vary the doctor’s 
traditional role as much as the CDSS.  The e-prescribing software is much 
more likely to be seen as a time and labor-saving tool the doctor manipulates 
than as an “electronic partner” in the decision-making process regarding the 
patient’s care.  Third, there is already a loud call for a move toward e-
prescribing, in the name of patient safety. 
 
 43. Palm Pilot is a registered brand name of the 3-Com Corporation.  By virtue of this 
brand’s popularity and ubiquity, “palm pilot” has become a generic label, like “Kleenex,” 
although there are a number of other brands of PDAs.  For information on the major brands, see 
800.com Electronics, at http://www.800.com (last visited Nov. 12, 2001). 
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B. Patient Safety Benefits 
E-prescribing addresses one of the most serious problems affecting patient 
safety: errors in ordering, dispensing and administering prescription drugs.  
This type of error has received considerable attention in the past couple of 
years, largely as a result of the Institute of Medicine’s (IOM’s) recent report, 
To Err Is Human: Building a Safer Health System.44  According to this widely 
cited and discussed research study, a whopping nineteen percent of all 
iatrogenic injuries are caused by medication errors.45  Errors come not just 
from the legendary difficulties in reading doctors’ handwritten (or scrawled) 
prescriptions, but also from a failure to identify and/or anticipate potential drug 
interactions.  This second piece—often an example of the left hand (of the 
treatment team) not knowing what the right hand is doing—highlights the 
desirability of moving toward a unified Electronic Medical Record.46 
The health care field has long recognized both the critical importance and 
the difficulty of maintaining a comprehensive patient medical record that is 
kept scrupulously up-to-date, and, for over a decade, influential groups have 
called for that record to be computerized.47  When a patient is under active 
care, there may be many different data elements generated in a single day and 
many different diagnostic and treatment decisions made.  Ideally, each 
decision should be made with full knowledge of all other care decisions made 
or pending, of all aspects of the regimen the patient is embarked upon, and the 
most complete and current information about how that regimen is progressing.  
Unfortunately, even with a system organized to place principal coordinating 
responsibility on a single individual, the attending physician, that ideal is 
commonly not achieved.  Diagnostic test results come in from various sources 
at their own speed.  Specialists treating various aspects of the patient’s 
condition do not necessarily communicate their actions and findings 
immediately to the attending physician.  The attending physician, even when 
she is doing her best to touch all bases and gather all information before 
making a decision or taking an action, too often has to go forward with one or 
more pieces of information missing or questionable.  A unified electronic 
record simultaneously accessible to all authorized persons dealing with the 
patient, either directly or indirectly (that is, either as a hands-on provider or, 
say, a laboratory analyzing a specimen delivered to it at a remote location), has 
 
 44. COMM. ON QUALITY OF HEALTH CARE IN AMERICA, INST. OF MED., TO ERR IS HUMAN: 
BUILDING A SAFER HEALTH SYSTEM (Linda T. Kohn et al. eds., 2000). 
 45. Id. at 221. 
 46. See, e.g., White Paper Proposes Elimination of Handwritten Prescriptions by 2003, 
MED. INFO. TECH. L. REP., Nov. 2000, at 1, 5. 
 47. See, e.g., COMM. ON IMPROVING THE PATIENT RECORD, INST. OF MED., THE 
COMPUTER-BASED PATIENT RECORD: AN ESSENTIAL TECHNOLOGY FOR HEALTH CARE 
(Richard S. Dick & Elaine B. Steen eds., 1991). 
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long been a dream.  That dream is on the verge of becoming a reality, 
especially within an integrated delivery system (IDS), such as a health 
maintenance organization (HMO), where everyone who deals with the patient 
is part of the same system, has access to the same computer network and plays 
by the same procedural rules. 
Even without a fully integrated delivery system network, however, it is 
currently possible in many areas to develop a functional e-prescribing 
system.48  That is because PBMs, or Pharmacy Benefits Managers,49 and even 
chain retail pharmacies currently maintain fairly sophisticated pharmacy 
computer systems that track drug-related information for their client-
customers.  Prescriptions, including those entered through traditional 
handwritten “scripts,” are logged into a computer system as they are received 
and filled.  This information can be shared with every pharmacy in the system, 
as well as with those in other prescription-tracking systems that maintain 
reciprocal, cooperating relationships.  It can also be shared with the patient’s 
physician and any third-party payer responsible for the patient’s care.  Many of 
these systems are programmed to screen for possible drug-drug and drug-diet 
interactions, dosage errors, allergy screening, prescription duplication, special 
safeguards for geriatric and pediatric patients, IV compatibility checks, drug-
disease contraindications, et cetera.50 
C. Convenience and Cost Savings 
A simple and readily achievable benefit of e-prescribing is that the patient 
is spared the inconvenience of taking a handwritten prescription to the 
pharmacy, handing it in and waiting, sometimes for an hour or more, for the 
prescription to be filled.  Assuming an office visit with the physician has 
generated a prescription, it can be electronically entered, and the prescription 
can be processed and waiting to be picked up when the patient arrives at the 
pharmacy.  The initial cost of setting up these e-prescribing systems may be 
substantial, but it will be justified by the marketing benefits to be expected 
from them.  Moreover, once patients have become accustomed to having their 
prescriptions handled this way, they will prefer to deal with pharmacies that 
 
 48. E-prescribing is a logical, incremental step toward a fully computerized practice 
environment.  See, e.g., Bruce Kleaveland, Incremental Approach to Electronic Medical Records, 
HEALTH MGMT. TECH., June 2001, at 18. 
 49. For an introduction to PBMs generally, see Arnold J. Rosoff, The Changing Face of 
Pharmacy Benefits Management: Information Technology Pursues a Grand Mission, 42 ST. 
LOUIS U. L.J. 1 (1998) [hereinafter Rosoff, Changing Face of Pharmacy Benefits Management]. 
 50. Salvatore M. Barcia, Reducing Medication Errors, HEALTH MGMT. TECH., Jan. 2001, at 
26.  Note that some of the functions mentioned above—such as drug-food interactions, allergy 
screening and drug-disease contraindications—are feasible only in systems that track more than 
just pharmaceutical-related information.  The comprehensiveness and sophistication of extant 
systems varies considerably. 
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participate in such a system.  The MCO that sets up and operates the system 
will exert considerable influence over the patient’s purchasing behavior and 
can parlay this influence into bargaining power with pharmacies that want to 
be participating providers.  To the extent that the bargaining power lowers 
prices and the savings are shared with the patient-consumer, the above 
relationship is further reinforced and solidified.51  The physician-patient-
pharmacy-payer network offers great potential.  It is by no means certain that 
MCOs will take advantage of this potential; but it exists and it seems likely—
subject to a reservation to be discussed shortly—that in today’s highly 
competitive healthcare environment, some MCOs will do so.  When that 
happens, competition will dictate that (at least some) others will follow suit. 
D. Compliance with Managed Care Formularies 
Over the past several years, MCOs have increasingly used formularies to 
help control runaway prescription drug costs.  Formularies are lists of drugs 
approved by a governing body—typically called a Pharmacy & Therapeutics 
or “P&T” committee—for use in care rendered in a given institution or through 
a particular health plan.  MCOs use formularies to identify which drugs they 
would prefer their affiliated physicians to use in treating plan members. 52  
Although it is possible for a formulary to be “closed”—meaning, the physician 
can use only drugs included on the formulary list—it is far more common for a 
plan to maintain an “open” formulary.  This is because it is politically very 
sensitive to try to control the doctor’s ultimate choices with regard to the 
patient’s treatment and, beyond politics, such domination of the physician’s 
judgment poses significant legal risk.  Numerous cases have held that a 
managed care entity can become liable when it “takes the reins” and tries to 
control the physician too completely.  Influencing the physician’s judgment 
may be acceptable; overweighing it clearly is not. 53 
But the choice is not a simple dichotomy between a closed and an open 
formulary; different degrees of freedom—or degrees of constraint, if one is 
disposed to see things in a “glass half empty” kind of way—are possible.  A 
health plan’s drug benefit can be set up so that if the physician prescribes for 
his patient a drug “preferred” by the plan’s formulary, there is no charge to the 
 
 51. Commenting on a draft of this article, the author’s principal pharmaceutical industry 
source, consultant Elan B. Rubinstein, Pharm. D., M.P.H., of Oak Park, California, was skeptical 
that such savings would be passed through, at least in any direct way, to consumers.  An indirect 
savings might be possible, however, in that MCOs might save money on their drug benefit 
coverage and some of that savings could find its way to members in the form of lower premiums.  
E-mail correspondence with Dr. Elan B. Rubinstein, Nov. 10, 2001. 
 52. See Rosoff, Changing Face of Pharmacy Benefits Management, supra note 49 
(discussing the use of formularies by PBMs). 
 53. BARRY R. FURROW ET AL., HEALTH LAW: CASES, MATERIALS AND PROBLEMS 559-60 
(4th ed. 2001) and references cited therein. 
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patient for the medication—except, perhaps, a basic pharmacy visit co-
payment (dispensing fee).  On the other hand, if the physician prescribes a 
“non-preferred” drug—most likely one that costs the plan more money and for 
which there is no pharmaco-economic proof that it yields a better outcome—
the patient has to pay significantly more.  The potential that e-prescribing 
offers to deal efficiently with information makes possible a new range of 
options for maximizing cost savings in ordering pharmaceuticals.  Consider the 
following hypothetical: 
Dr. Y has diagnosed his patient, Mr. D as having a chronic illness that requires 
treatment with drugs.  Of the four or five drugs that could be used, drugs #1 
and #2 seem most appropriate for a person of D’s age, gender and co-
morbidities.  Drug #1 is preferred by D’s MCO because it costs the plan 20% 
less.  However, for some 15% of the patients suffering Mr. D’s condition, drug  
#1 has side effects that, although not seriously health-threatening or 
permanent, are unpleasant (assume such effects as dry mouth, headache, 
disturbed sleep or stomach upset).  Drug #2, costing 20% more, rarely causes 
any side effects.  Over the years, Dr. Y has adopted a personal policy of always 
prescribing drug #2 because he does not want to risk his patient’s discomfort 
and also does not want to take the time to explain the possible side effects and 
what to do if they occur.  But now, in an atmosphere of heightened cost-
consciousness, one of the health plans with which Dr. Y participates is putting 
pressure on him to use the cheaper drug whenever possible.  For the doctor to 
remember which plans prefer which drugs and which patients are covered by 
which plans is a significant burden,54 particularly given Dr. Y’s busy practice 
schedule. 
Let’s assume first a situation without e-prescribing: 
Dr. Y handwrites a prescription for Drug #2 and gives it to Mr. D, who takes it 
to his local pharmacy to be filled.  D has to wait half an hour for the 
prescription to be filled and when he steps up to the counter to pay, he is 
shocked by how high the price of the drug is.  D knew he would have to pay a 
nominal dispensing fee but thought his health plan would pay the actual cost of 
the drug.  He complains to the pharmacist that there must be some mistake 
because he pays extra for a health plan that supposedly has a good drug 
benefit.  The pharmacist explains to him that he has to pay more because he is 
getting a drug that is not the “preferred” drug in the plan’s formulary.  He also 
explains why this matters for reimbursement purposes and, further, that D’s 
physician, who undoubtedly has access to the plan’s formulary guidelines, 
could have recommended the cheaper drug.  He speculates that maybe Dr. Y 
was trying to avoid a side-effect D had experienced on some previous occasion 
when using the cheaper drug, but D interrupts to say that could not be the case 
 
 54. Note that, given the way PBMs, health plans and other third-party payers negotiate with 
pharmaceutical companies, a drug that is cheaper for one plan is not necessarily cheaper for 
another, making it harder for the doctor to keep in mind which is the preferred drug for a given 
plan. 
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because he has never before been treated for this condition and, so, he has had 
no experience with any drug of the type in question.  D is annoyed that his 
physician made a decision that required him to incur a significant out-of-
pocket cost without even mentioning this to him.  D’s annoyance could also 
extend to the MCO for its perceived cheapness in not covering the drug his 
doctor thought was best for him and even to the pharmacist, who filled the 
prescription while D was in the store but did not mention the price difference 
until it was time for D to take his drugs and pay the bill.  The point is that 
“business as usual” today has real potential for causing consumer 
dissatisfaction and adding to “managed care backlash.” 
Now, let’s consider how the same situation might have played out if Dr. Y 
were using an e-prescribing (e-Rx) system: 
Upon diagnosing Mr. D’s condition, Dr. Y would have picked up his PDA and 
easily pulled up a menu listing the drugs that could be used to treat it.  
Information would have been instantly available on the possible 
contraindications, including side-effects, of each drug.  Upon entering the 
patient’s name or identification number, Dr. Y would have seen if D was 
currently taking any other drugs that might pose a drug-interaction problem.  
He would also have seen what health plan D was enrolled in, and that plan’s 
formulary information would have been displayed on the screen.  With this 
reminder of which drugs were preferred in that plan and which were not, Dr. Y 
could easily have told D of the cost difference and asked whether that was 
significant to him or not.  The conversation about possible side effects of the 
cheaper, preferred drug would have taken place at that point, heading off the 
patient’s surprise and displeasure later on.  The decision, reached jointly, 
would have been communicated instantaneously when Dr. Y clicked on the 
button for the chosen drug and pushed “enter” and the prescription, already 
filled, would be waiting for Mr. D when he arrived at the pharmacy.  The 
safety benefits of not having to deal with a handwritten script have already 
been noted. 
The potential benefits of the e-prescribing system do not stop here.  
Presumably, most managed care companies, while intent on saving money, 
would be willing to pay the extra cost of the more expensive drug (#2) in those 
specific cases (assumed to be fifteen percent in the above hypothetical) where 
it is needed, that is, where a patient actually experiences the unpleasant side 
effects associated with the cheaper drug (#1).55  Given the convenience and 
information-tracking ability of the e-prescribing system, Dr. Y could be 
authorized to make the following sort of offer to his patient: 
“Mr. D, your plan will only cover the cost of the more expensive drug when it 
has been shown that the drug is actually needed for a particular patient.  If you 
want, I can start you on a short course of the cheaper drug, #1.  I’ll explain the 
 
 55. Elan Rubinstein cautions that insurers will not necessarily be willing to pay hard dollars 
to avoid patient’s unpleasant side effects or inconvenience.  See supra note 51. 
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negative side-effects you might possibly experience with it and give you a 
print-out that details the symptoms to watch for.  If any occur, you let me 
know and I’ll switch the prescription immediately.  The pharmacy will deliver 
a substitute prescription of drug #2 to your home, with no charge for the drug 
or the delivery, and you can simply discard the unused portion of drug #1.  
Thereafter, if refills are needed, your health plan will pay for the more 
expensive drug without any additional charge to you.  How does that 
sound?”56 
That would probably sound quite good to most patients.  This positive 
outcome is possible because the information specificity of e-prescribing makes 
it practicable to tailor each prescription to the particular patient and avoid 
wasteful “excess of caution” approaches, such as Dr. Y employed in the 
original hypothetical. 
E. Documentation for Reimbursement Purposes 
This next point is directed not just to e-prescribing but, more broadly, to 
the use of Point-of-Care systems generally, and particularly to the use of hand-
held devices (“PDAs”) by the physician at the time of contact with the patient.  
Careful accounting of the time spent attending to patients is an important part 
of the reimbursement (billing and payment) process.  As third-party payers, 
both private and governmental, have become more sensitive to and wary of 
problems of overbilling, “upcoding”57 and charging for services as if they were 
rendered by a senior physician when, in fact, they were rendered by one less 
qualified (and thus commanding a lesser reimbursement rate), the precision 
and accuracy of accounting for healthcare practitioners’ time has become more 
of an issue.  Ratcheting up the care with which mundane accounting tasks have 
to be handled is inconsistent with the more time-pressured and frenetic pace of 
practice today.  Therefore, what is needed is a way of recording care provided 
more efficiently—meaning, generating records that are more accurate, precise, 
reliable and unassailable while consuming less of the provider’s time in doing 
so. 
PDAs offer the potential of accomplishing this win-win objective.  With a 
well-designed POC system, when the physician turns his or her attention to the 
patient, this is signaled by picking up the PDA and accessing the patient’s file.  
The doctor’s arrival at the bedside can be documented by scanning a bar code 
at the foot of the bed.  All of the information called up while that file is open—
 
 56. Dr. Rubinstein points out that in today’s work – and perhaps into the future as well – the 
physician might approach this situation by giving the patient a free sample of the cheaper drug 
(#1).  The impact of giving “free samples,” a relatively common practice in today’s 
pharmaceutical marketplace, is hard to assess, since these transactions bypass the normal 
channels for tracking use of prescription drugs.  See supra note 51. 
 57. See generally United States v. Krizek, 859 F. Supp. 5, 8-9 (D.C. Cir. 1994), rev’d 111 
F.3d 934 (D.C. Cir. 1997) (demonstrating the use and perils of “upcoding”). 
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lab and X-ray reports, nursing records of the patient’s progress and reaction to 
medications, recording of vital signs, et cetera—helps to document that the 
physician was working with and thinking about that patient during that time 
period.  Any treatment or diagnostic orders entered by the physician using the 
PDA also helps to accurately document the physician-patient interaction.  
When the physician logs out, or calls up the records of another patient, or when 
a pre-set amount of time elapses without any activity on the PDA, that signals 
and records the end of that treatment encounter.  No longer should there be 
difficult factual questions concerning whether, for example, the physician’s 
visit with the patient is properly classified as long, short or intermediate.  The 
PDA will know and will record this information automatically in a system that 
routinely tracks this kind of information.  It also can be programmed to bill the 
third-party payer for the physician’s service in the way authorized by the 
relevant reimbursement protocols, eliminating much of the cumbersome paper 
burden that currently bogs down clinical practice and makes it tedious. 
F. How Will E-prescribing Change Doctor-Patient Relationships? 
It was speculated above that Clinical Decision Support Systems, despite 
their potential for improving the quality of patient care, might have the ironic 
side-effect of lowering physicians’ stature in their patients’ eyes.  The 
relational aspects discussed under the CDSS section are somewhat the same 
here, but would seem to be less problematic.  While the physician’s PDA 
might prompt him or her in the same way as a CDSS does, it would probably 
not be as likely to seem controlling; that is, it would be seen more as a tool in 
the doctor’s hands than an electronic  “partner” sharing decision-making power 
with her or him. 
As discussed above, the physician’s interaction with the formulary will be 
streamlined in ways that can yield both convenience and cost-saving benefits 
to the patient.  When the electronic tool visibly and palpably yields benefits for 
the patient as well as the physician, patients can be expected to support its use.  
The pharmaceutical and handheld device industries will likely be supportive 
too, because of the market implications of this development; however, as 
discussed below, the nature and extent of their support may be constrained by 
legal considerations. 
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G. Practical and Legal Considerations 
The move to e-prescribing will take time and will pose some tough 
challenges.  Perhaps more than other practice innovations, e-prescribing may 
prove an extreme case because it has so many different elements.  First, it 
represents a change in a system that has been firmly entrenched for a very long 
time.  For generations, physicians have been handwriting paper prescriptions 
and giving them to patients to have them filled in a “drug store” marketplace of 
the patient’s choice.  A change to e-prescribing requires not just a shift in the 
physician’s own practices, such as, swapping a pad for a PDA; it also entails 
tying the physician in with a large and complex system that involves health 
plans, pharmacy chains and often PBMs, as well as the vendors and others who 
work directly with the e-Rx systems.  The change involves new hardware, the 
handheld device, the cost of which is not insignificant; but, beyond that, the 
individual doctor’s PDA has to connect with an intricate data bank and 
information system.  The cost of refining that system to enable it to link with 
the handheld devices will be substantial and will be reflected in the end-user 
price of the e-Rx service.  The cost of that service will be large enough that 
physicians will be hesitant to pay for it themselves,58 especially since, as will 
be discussed below, it will likely be unclear at the outset which e-Rx system(s) 
ultimately will prevail.59 
Given our pluralistic economy, e-prescribing systems will undoubtedly be 
proprietary, with numerous competitors each jockeying for its niche in the 
marketplace.  However, the overall effectiveness of all e-Rx systems will be 
greatly compromised if there is not a relatively free exchange of large amounts 
of data from one proprietary system to another.  For example, if a patient gets 
one prescription from a physician affiliated with his MCO and has it filled at a 
CVS pharmacy, then sees another physician not affiliated with that MCO and 
gets a second prescription, which he has filled at a Rite-Aid store, the 
electronic system will fail—perhaps with disastrous consequences—unless the 
CVS and Rite-Aid systems “talk” to each other and share this information.  If 
the two retail chains use different data-handling systems, those systems will 
have to be compatible and be able to “query” each other electronically while 
respecting the rights each participating system has in its own proprietary 
information.60  Moreover, everything has to be handled in a way that assures 
 
 58. But see ISMP White Paper, supra note 42, at 12, which asserts that “it is probably safe to 
say that clinicians can obtain electronic prescribing capability at what may be a surprisingly low 
cost of entry.” 
 59. Recall the contest in the early days of VCRs between Sony’s Beta format and the VHS 
format, which latter eventually became the industry standard, turning Beta systems into useless 
white elephants! 
 60. Of course, to the extent that the patient’s drug purchases are handled through his or her 
MCO or a PBM, coordination will be much more likely, since mechanisms for information-
sharing through those channels are already fairly well established. 
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patient confidentiality will be unfailingly maintained.  This is no small order.  
Fortunately, we are not starting from scratch in this monumental undertaking; 
progress in the electronic storage and sharing of prescription drug information 
has been ongoing for well over a decade, and there is a substantial 
infrastructure of electronic and contractual networks to build upon.61  Still, 
there are a number of intertwined, knotty issues that will have to be 
surmounted before an effective, comprehensive e-prescribing system can be 
implemented.  The following discussion highlights the major ones. 
1. Technical issues with wireless handheld systems 
The utility of e-prescribing will be greatly compromised if it has to be tied 
to desktop computers.  Mobility is key to adoption and use by physicians, who 
do much of their ordering of tests and prescriptions at the patient’s bedside 
while making rounds, or otherwise on the move.  That is why the development 
of e-prescribing systems has focused on the use of handheld devices, or 
PDAs.62  Moreover, PDAs will be compromised if they have to be connected 
by wire to the data source.  This dictates the use of wireless systems, connected 
by radio or infrared light to an institution-based (meaning, hospital, nursing 
home, et cetera) network.  One problem that has surfaced in the early stages of 
development of these systems is the possibility of interference from other 
electronic devices in the hospital environment.  This is a technical problem and 
presumably a detail that can be worked out.63  It is mentioned here because 
such details are the inevitable bumps in the road toward a technologic future 
world.  With rare exceptions, such problems get solved in time.  The question 
is how much time . . . and at what cost?  The pace of adoption of computer 
technology over the past few decades has been staggering.  It is tempting to 
assume that pace will continue, but a flagging economy could slow it 
substantially. 
 
 61. Rosoff, Changing Face of Pharmacy Benefits Management, supra note 49, at 1. 
 62. See ISMP White Paper, supra note 42. 
 63. See, e.g., Don Witters, Medical Devices and EMI: the FDA Perspective, at 
http://www.fda.gov/cdrh/emc/ persp.html (last visited Jan. 16, 2002); Jeffrey M. Gilfor, Report on 
Electromagnetic Interference in Hospitals: Debunking an Urban Myth, at 
http://www.rnpalm.com/EMI.htm (last visited Jan. 16, 2002); Jay Wrolstad, Study: Cell Phones 
Interfere with Medical Devices, at http://wireless.newsfactor.com/perl/printer/6567.html/ (last 
visited Jan. 16, 2002); Bill Saltztein, Where Have all the Cables Gone?, at 
http://www.codebluecommunications.com/Documents/Bluetooth%20Monaco%20article.pdf (last 
visited Jan. 16, 2002); U.S. Food and Drug Administration, Performance Plan (2002), at 
http://www.fda.gov/ope/fy02plan/part2_cdrh.html (last visited Jan. 16, 2002); Amendment of 
Parts 2 and 95 of the Commission’s Rules to Create a Wireless Medical Telemetry Service, at 
http://www.fcc.gov/Bureaus/Engineering_Technology/Notices/1999/fcc99182.txt (last visited 
Jan. 16, 2002). 
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2. Security of transmitted information 
Another “technical detail” that goes to the very core of the feasibility of 
medical PDAs is the security of confidential patient data.  Data security and 
confidentiality generally are issues that by their very magnitude exceed the 
scope of this paper.  Fortunately, they are issues that have been covered in 
many other places and need not be visited in any substantial way here.64  
Suffice to say, it is assumed that some combination of advancing technology, 
marketplace creativity and government regulation will provide a satisfactory 
answer to the problem.  If it does not, then most of what is projected in this 
Article may simply not come to pass.  Data security is the sine qua non of the 
electronic age in healthcare.65  Many companies that have staked their futures 
on supporting POC systems claim to have “secure solutions,” some of them 
using a proprietary intranet instead of the more accessible and, presumably, 
less secure Internet.66  And, of course, the federal government has weighed in 
heavily with the Health Insurance Portability and Accountability Act (HIPAA) 
legislation,67 which has seemingly generated an entire compliance industry.68 
3. Fraud and Abuse Implications 
As noted above, the significant cost of the needed handheld devices is a 
possible impediment to the implementation of e-prescribing.  Attempting to 
counter this cost obstacle to adoption, pharmaceutical distributors and retailers, 
especially large drug chains or PBMs, might provide PDAs to physicians with 
the vendor’s system software pre-loaded to ease the transition to e-
prescribing.69  The vendor might also provide instruction on how to use the 
supplied devices and technical support, such as a toll-free telephone “help 
desk,”—for those who wish to participate in its system.70  Recruiting 
 
 64. See, e.g., COMM. ON QUALITY OF HEALTH CARE IN AMERICA, INST. OF MED., 
CROSSING THE QUALITY CHASM: A NEW HEALTH SYSTEM FOR THE 21ST CENTURY 171-74 
(2001) [hereinafter CROSSING THE QUALITY CHASM]. 
 65. See, e.g., Cyberhealth – Hand-Held Rx Security, HEALTH MGMT. TECH., Nov. 2000, at 
8. 
 66. Richard R. Rogoski, LIS Shake-out, HEALTH MGMT. TECH., June 2001, at 14-16; 
Doylestown Hospital to Participate in DrFirst.com’s Pilot Program for RcopiaSync, the Newest 
Enhancement to its Electronic Prescription Management System, BUSINESS WIRE, Jan. 5, 2001. 
 67. Health Insurance Portability and Accountability Act, Pub. L. No. 104-191, 110 Stat. 
1936 (1996), cited in 29 U.S.C. §§ 1001-1461 (1994), 42 U.S.C. §§ 201-299 (1994), 26 U.S.C. §§ 
1-9806 (1994 & Supp. 1996) [hereinafter HIPAA]. 
 68. Sale of Prescription Information Subject of Lawsuit, THE MED. INFO. TECH. L. REP., 
July 2001, at 5-6; Privacy Turmoil Continues, THE MED. INFO. TECH. L. REP., Mar. 2001, at 1-3. 
 69. ISMP White Paper, supra note 42, at 12. 
 70. The following twist on this approach raises an even higher legal risk.  Since there will be 
competing networks, physicians might seek participation in two or more of them, perhaps getting 
multiple PDAs, but ultimately using one of them very little or not at all for e-prescribing.  
Obviously, companies supplying PDAs and other support would want to be sure they are getting 
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customers to use an e-prescribing network by offering goods and services 
might seem like simply good business—assuming, of course, that the cost of 
these things is justified by the long-term revenues to be expected from the 
network.  However, there is a serious risk in this approach.71  The federal laws 
concerning “fraud and abuse” make it a felony to offer or give anything of 
value in return for referrals for goods or services paid for under federal 
healthcare programs, most notably Medicare and Medicaid.72  To the extent 
that physicians use PDAs and/or e-prescribing systems supplied or subsidized 
by sellers of pharmaceuticals to enter prescriptions for drugs paid for under 
federal programs, this is arguably a violation.73  The severity of the sanctions 
possible under the fraud and abuse laws makes it critical that their application 
to this context be carefully considered. 
4. The Need for a “Common Platform” 
Another technical challenge that stands at the threshold of e-prescribing is 
the establishment of a “common platform”—or, at least, a system for ensuring 
compatibility of platforms—for the electronic devices used to link physicians 
with pharmacies, patient records and third-party payers.  At the core of the 
purpose and power of POC systems is their ability to access data from many 
 
their money’s worth for their investment.  Thus, e-prescribing firms might naturally think of 
offering deals whereby “forgiveness” of the cost of the PDA would be based upon the volume of 
e-prescribing the physician did in a given timeframe.  Any arrangement that ties the provision of 
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laws. 
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different sources, subject it to common processing and analysis, and send it 
back out to the various authorized parties in the data network—all seamlessly 
and transparently.  The use of multiple, incompatible systems is fundamentally 
inconsistent with this objective.  Yet, in the early stages of the movement 
toward e-prescribing, the industry is struggling to achieve an adequate level of 
standardization or compatibility.  Anything less would balkanize the field, and 
block attainment of its most desirable benefits. 
Responding to this problem, three of the largest players in the pharmacy 
benefits management (PBM) field have formed a coalition organization called 
RxHub to work toward the establishment of compatibility standards and a 
common platform for e-prescribing.74  The three companies—AdvancePCS, 
Express Scripts, and Merck-Medco—have together contributed twenty million 
dollars to fund the development of what they call an “electronic exchange” or 
“connectivity hub,” a portal through which physicians, PBMs, health plans and 
pharmacies can connect for information-sharing and e-prescription purposes.75  
In addition, RxHub will work with other organizations to establish universal 
electronic prescribing standards and a personal identification system to link 
members with a participating PBM and health plan.  RxHub claims that its 
connectivity hub “will improve the functionality of electronic prescribing by 
eliminating certain communication barriers.”76  Prior to the establishment of 
RxHub, dozens of different, potentially incompatible e-prescribing platforms 
were developed by PBMs in conjunction with various e-prescribing device 
(PDA) manufacturers, laying the foundation for an e-prescribing “Tower of 
Babel.”  RxHub says 
[its] ultimate goal is to create universal electronic prescribing standards 
analogous to the development of common claims transmission standards by the 
National Council for Prescription Drug Programs (NCPDP) which have 
enabled all retail pharmacy prescription claims to be transmitted in an identical 
format, regardless of the health plan or PBM receiving the information.77 
The three founding companies have issued an open invitation to other 
companies to join with them over time to help speed the development and 
spread the benefits of a common platform throughout the industry.  Agreement 
on standards to assure compatibility is crucial to achieving universal 
information-sharing capability, which, in turn, is necessary to meet calls to 
move to electronic prescribing with all deliberate speed.  Indeed, one 
 
 74. For more information about RxHub see http://www.rxhub.net/about (last visited Nov. 8, 
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organization, the Institute for Safe Medication Practices, has called for 
eliminating all handwritten prescriptions by 2003.78 
In addition to addressing the technologic and practical issues raised above, 
development of a common platform will speak to potential legal issues as well.  
Fraud and abuse concerns are lessened by the adoption of a common platform.  
If a given PBM provides a PDA or technical support for e-prescribing, it is less 
likely to be characterized as an attempt to induce referrals if the platform being 
supported can also be used to refer patients to other pharmaceutical suppliers.  
Antitrust concerns should be reduced as well, because the e-prescribing system 
would no longer serve to tie its users to a particular pharmaceutical supplier.  
With a common platform in place, the e-system becomes a facilitator of 
competition in the pharmaceuticals marketplace rather than a device to 
forestall competition. 
5. Physicians’ Adoption of the New Technology 
Assuming that the technical and legal impediments to e-prescribing can be 
worked out, there remains the non-trivial problem of getting physicians to use 
the systems.  At present, physicians’ familiarity and comfort level with 
computers, e-mail and other electronic applications varies widely.  It has been 
estimated that only about five percent of physicians e-prescribe.79  Physicians 
are bright people and generally quick to learn, but they are also widely seen as 
creatures of habit who can be stubbornly resistant to innovations in their 
practice environment.  This is particularly the case where the innovations are 
complex enough that their use requires substantial training.  Because 
physicians are so busy and commonly must process a large number of 
“transactions” each day, adoption even of time- and labor-saving devices and 
procedures poses a problem in the short run if it takes a fair amount of “gear-
up” time or effort.  This problem is especially acute when change in the routine 
way of doing things poses an increased risk of error during the adaptation 
period.  This last point could easily apply to e-prescribing—depending, of 
course, on how complicated these systems actually are to learn and to use.80  
Contrast, for example, two competing e-prescribing systems, one of which 
automatically flags potential drug interactions by checking for any other drugs 
the patient may be taking currently while the other requires the doctor to 
“query” the system for such information.  Particularly for physicians who may 
have occasion to work with two or more different systems—as, for example, 
 
 78. CROSSING THE QUALITY CHASM, supra note 64, at 166; ISMP, White Paper, supra note 
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 79. MargaretAnn Cross, Competitors Set to Launch Pharmacy Info Exchange, INTERNET 
HEALTH CARE MAG., Apr. 2001, at 6. 
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where a physician practices at a hospital and a nursing home—there is a danger 
of errors that could harm patients. 
Given the heightened risk of errors during the transition phase, the 
challenge is to get the e-prescription system set up and running, and get the 
physician fully oriented to its use in the shortest possible time.  In most cases, 
this will involve more than just supplying the device and an instruction 
manual.  Some training exercises will be required and, for a time at least, 
technical staff support will have to be made readily available.81  If this is not 
done, adoption of the e-prescribing system may be slowed or stalled, or 
perhaps even blocked entirely, as might be the case if a physician has a bad 
experience with his or her early use of the system.  The more difficult it is to 
master a new system—and the more new systems a physician has to master—
the more likely it is that adoption will be a troubled and protracted process, 
with a higher likelihood of patient harm occurring along the way.  Because of 
the difficulty of getting used to a number of different e-prescribing systems, 
and having to move back and forth among them if the doctor’s patients belong 
to different plans, the development and adoption of a “common platform” 
becomes extremely important.  Another variable that affects the rate of 
adoption of new technology is the type of organization in which the physician 
practices.  Those who are affiliated with large group practices, IPAs, or IDSs 
are more likely to be accustomed to working within an information system 
infrastructure.  They will also more commonly have technical staff available 
through their practice affiliation(s) to help them master new e-technology.  
Physicians in solo practice and small-group practices represent a much greater 
challenge.82 
IV.  THE DIFFICULT PASSAGE TO THE NEW E-WORLD 
Moving to the new e-world will not be easy.  As intriguing as it is to 
envision a healthcare practice environment where things are different, getting 
from here to there will take time and will pose difficulties.  The major 
difficulties foreseen are highlighted below. 
A. The High Cost of Getting There 
Any serious—as opposed to “pie in the sky”—discussion of the electronic 
era in healthcare has to address the massive costs of switching over to new 
technology and systems.  Virtually all of the CDSS and e-prescribing systems 
being developed and promoted, as well as the underlying Electronic Medical 
Record (EMR) systems upon which they largely depend, are based on state-of-
the-art web-based technology.  The systems currently in place in many health 
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care institutions are so-called “legacy systems,” meaning, old-technology 
systems left over from previous generations of computer applications.83  
Designed for use by hospitals, other providers, and health plans for billing, 
claims-handling and other administrative purposes, they are not “web-enabled” 
and will not support many of the functions discussed here.  To scrap the old 
systems and move whole organizations into the new ones is a massive 
undertaking, not just in terms of direct system costs, but also in terms of 
personnel retraining and decreased productivity during the transition period.  
The cliché sign “Temporary inconvenience . . . permanent improvement” hints 
at, but understates, perhaps grossly, the complexity and cost of bringing about 
the desired change. 
Unlike some transitions, where things can be done piecemeal, the move to 
the kind of e-health innovations considered here is much more of an all-or-
nothing affair.  Given the importance of wide-scale information-sharing, there 
must be a very high level of systems compatibility for things to work properly.  
This is true with regard to a single organization—an academic medical center, 
say—but even more so when considering aspects of integration that span the 
entire healthcare system.  Moreover, whether with regard to CDSSs, e-
prescribing or EMRs, there is not a single, “anointed” system just sitting there 
waiting to be adopted.  Rather, there are competing systems and approaches, 
some of which, presumably, will succeed and survive while others fail and 
disappear.  When considering whether to invest millions of dollars in a new 
system and accompanying technology upgrade, healthcare organizations 
legitimately fear being a too-early adopter and heading off in the wrong 
direction.  Recalling, perhaps, the Beta-VHS face-off in the VCR revolution of 
the 1980s, many now considering e-health systems are waiting for others to 
point the way.  They will come along only after they are confident they know 
which way things will go.  Recognizing the massive systems investments 
required to change the industry, the Institute of Medicine has called for “a 
renewed national commitment to building an information infrastructure . . . .”84 
and has specifically recommended that Congress create a one billion dollar 
Health Care Quality Innovation Fund to help support this development.85 
As if the above cost problems were not enough, the current downturn in 
the economy, particularly in the tech and Internet sectors, has arguably slowed 
the progress.  Several well-known companies have gone out of business, and 
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many others have been acquired or are up for acquisition.86  Even such front-
running companies as drkoop.com are feeling the pinch; its stock fell to a 52-
week low of six cents a share on October 3, 2001.87  While the decline of this 
market sector will slow progress in countless ways, it may also offer some 
benefits.  The shakeout will inevitably bring consolidation, the strongest 
companies will survive, and the market that remains will have a smaller 
number of more widely adopted formats.  Since one impediment to progress in 
this area is agreement on “common platforms,” market factors that weed out 
the outliers may exert a useful, if painful, Darwinian evolutionary force on the 
entire field. 
B. Physicians’ Resistance to the Use of E-tools 
Concerns about physicians’ reluctance to adopt new tools and new ways of 
doing things are indeed significant, but may be overblown.  Stories of 
physicians’ behavior run both ways.  They can be as curious as they can be set 
in their ways, as pragmatic as they can be rigid; much depends on their 
environment and the way they are approached to consider changes.  
Particularly with regard to computer usage, problems of slow adoption may 
fade rapidly as a new generation of physicians takes the stage.  Younger 
physicians, having had the opportunity to hone their computer skills from 
grade school on, are comfortable with the equipment and bring an intuitive 
understanding to its use.88 
Increasingly, there are claims that physician reluctance is disappearing, 
particularly when savings in time, effort and money can be convincingly 
demonstrated.89  Adoption numbers should go up exponentially because with 
increased use it is possible to document a positive return on investment.  
Emerging statistics confirm what some have assumed from the beginning 
while others have doubted, that is, that use of computer tools does increase the 
efficiency and productivity of the practice.  Early anecdotal accounts pointed 
some potential users away, since the difficulties of getting new systems up and 
running efficiently, working out bugs and maintaining physician “buy-in” 
during the teething process have all been troubling matters. 
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In a statement reminiscent of Dr. Homer Chin’s about the use of CDSSs,90 
David Lacher, M.D., research medical officer of the National Center for Health 
Statistics in Hyattsville, Maryland says, “[i]f an application saves time, is easy 
to use, and reduces overhead, physicians will find ways to use it.”91  It is 
possible to prove substantial time savings in the use of computers—as, for 
example, the amount of time saved by not having to pull charts to get 
information about patients before making a treatment order, writing a 
prescription, et cetera.  But the irony, true in so many applications of 
computers, is that physicians are reluctant to use computer applications 
because of the time required to learn how to use them.  The busier a person is, 
the more important the time savings possible through computer use, but also 
the more reluctance the person may have to using computers initially.92 
“Train up a child in the way he should go, and when he is old he will not 
depart from it,” goes the old saying.93  Recognizing the importance of getting 
physicians acclimated early to the new world of healthcare, some medical 
schools are making special efforts to incorporate PDAs and their applications 
into the curriculum.  One example is Wake Forest University’s Baptist Medical 
Center, in North Carolina, where medical students are required to use mobile 
handheld devices throughout their medical training.94  Medical information 
technology companies are enthusiastic supporters of such training programs, at 
times providing equipment and technical assistance.95  The benefits to 
academic institutions and their e-industry partners can be substantial, both in 
terms of reputation and credibility and more concrete aspects, such as joint 
research to develop products that will be more useful and acceptable to 
physicians.96  Ultimately, though, it may be “demand-pull” from computer- 
and web-savvy patients, not the “supply-push” from technology developers 
and vendors that drives physicians to adopt the new technologies.97 
Finally, progress in the area under discussion is likely to be exponential.  
Once a solid foundation of EMRs is established, the expanded applications will 
start to flow.  Things will come together: CDSSs, e-prescribing, disease 
management, et cetera, to name just a few.  There are educational synergies 
and complementarities that will move things along as soon as some momentum 
is established. 
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C. The Digital Divide 
No discussion of the changes the electronic revolution will bring to 
medical practice would be complete without reference to the “digital divide,” 
the modern-day equivalent of the age-old dichotomy between the “haves” and 
the “have-nots.”  In today’s world, the have-nots are those who lack access to 
computers and the Internet, either because they do not have the needed 
equipment or lack the knowledge to use it.  Often, discussions of the digital 
divide in healthcare are focused on the patients’ side, with reference to the fact 
that many members of the general public do not have access to e-mail, use of 
the Internet, and the ability to help maintain and access their electronic medical 
records.  However, there are some positive views on this issue.  The IOM 
reports that “[t]he share of households with Internet access grew from 26.2 
percent in December 1998 to 41.5 percent in August 2000, an increase of 58 
percent in 20 months.”98  On the physician side, too, there is a significant 
digital divide, but that is, presumably, easier to rectify.  When a physician 
comes to believe that her practice is being held back by lack of e-devices, she 
will respond by obtaining such devices and learning how to use them.  
Moreover, as noted above, there is evidence that physician use of computers is 
going up.99 
V.  CONCLUSION 
This Article has attempted to project how the future world of physician 
clinical practice will evolve and to provide some insight into what it will be 
like to be a doctor in the digital, or electronic age.  That new practice 
environment is coming; and, despite jerks and false starts along the way, it will 
likely come sooner rather than later.  It will be a world of connectivity, where 
the doctor does not function alone, but rather, in concert with a large and 
sophisticated network for information-gathering and analysis.  The notion of a 
physician who relies solely on his or her own knowledge and judgment will 
have to be abandoned, and there may be some professional “sadness” about 
this.  But a new notion, based on technical competence and the ability to do 
things far more important and impressive for patients, will replace it.  All 
things considered, it will be a better world that all of us, providers and 
consumers of healthcare services alike, will ultimately welcome. 
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